New AstraZeneca drug reduces heart patients’ risks
BARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says.
Researchers followed 18,624 patients worldwide from 2006 to 2008. About half the patients were taking clopidogrel, also known as Plavix, while the other half were taking an experimental drug called ticagrelor, or Brilinta, made by AstraZeneca PLC.
Those on Brilinta had a 4.5 percent chance of dying, versus a 5.9 percent death risk for patients on Plavix, the world’s second-best selling medication made by France’s Sanofi-Aventis SA and U.S. drugmaker Bristol-Myers Squibb Co.
Doctors also found Brilinta was safer for patients since they were less likely to have bleeding problems, one of Plavix’s known side effects. Ticagrelor had its own adverse effects, including breathing and heart rhythm abnormalities.
The study results were announced Sunday at the European Society of Cardiology meeting in Barcelona, and also published online in the New England Journal of Medicine. The research was paid for by AstraZeneca.
For years, Plavix has been the standard anti-clotting treatment, though another drug, Prasugrel, made by Eli Lilly, became available earlier this year. Heart patients often take blood thinners like Plavix to avoid more serious problems in the future.
Brilinta is not yet on the market. If drug regulatory agencies eventually approve it, some experts predict it will be a best-seller. “It will become the new standard of care,” said Dr. Douglas Weaver, immediate past president of the American College of Cardiology.
“It’s more effective (than Plavix) and appears to be even safer,” said Weaver, who was not linked to the study.
Still, drug regulatory agencies typically take years to approve new drugs.
Not everyone was as optimistic about Brilinta being able to crowd out the available blood thinners.
“It means we will have a third option and the practitioner will have to make a very thoughtful decision about which of the three options is best for a given patient,” said Dr. Clyde Yancy, medical director of the Baylor Heart and Vascular Institute in Dallas and president of the American Heart Association.
Yancy said more information was needed on how the drug works to understand its side effects. “We don’t want to change things overnight,” he said. “(But) this is another option.”
_____
On the Net:
www.escardio.org
www.nejm.org
Related News
Catalyst says it sees evidence its drug vigabatrin is effective despite failures; study surgesOctober 1st, 2009 Catalyst plans more tests of anti-addiction drugNEW YORK — Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective.
Clinton discusses battling drug violence, organized crime with Mexican foreign ministerSeptember 26th, 2009 Clinton discusses fight against drugs with MexicoNEW YORK — U.S. Secretary of State Hillary Rodham Clinton and Mexican Foreign Minister Patricia Espinosa have vowed to "keep strengthening" cooperation in the fight against drug violence and organized crime that spills across their countries' common border.
Study shows experimental drug cuts stroke risk in patients with irregular heartbeatsAugust 30th, 2009 Study shows experimental drug cuts stroke riskBARCELONA, Spain — An experimental drug reduces the stroke risk in patients with irregular heartbeats by nearly four times, compared with the popular drug warfarin — but possibly at a cost, according to new research released Sunday. Patients taking the new drug dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim, also were slightly more likely to have heart attacks or stomach pain, according to the research presented at the European Society of Cardiology meeting in Barcelona.
New anti-clotting drug reduces heart patients' chances of dyingAugust 30th, 2009 New drug reduces risks for heart patientsBARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared to the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008.
Big pharma: Prescription sales and growth trends of the world's top 20 drugmakersAugust 7th, 2009 Ranking Rx: Top 20 drugmakers by annual salesRankings of the world's Top 20 drugmakers, based on global prescription drug sales for the year ending in March 2009, when total pharmaceutical industry revenue grew about 5 percent to more than $720 billion. Figures do not include revenue of company units selling consumer and animal health products, medical devices or diagnostic products.
Strong sales, cost cuts boost drugmaker Bristol-Myers Squibb's 2Q profit 29 percentJuly 23rd, 2009 Strong sales boost Bristol-Myers 2Q profitTRENTON, N.J. — Bristol-Myers Squibb Co.
Eli Lilly 2nd-quarter profit rises 21 percent, drugmaker increases full-year earnings guidanceJuly 22nd, 2009 Eli Lilly 2Q profit rises 21 percentINDIANAPOLIS — Eli Lilly & Co. said Wednesday its second-quarter profit rose 21 percent as stronger drug sales helped blunt the impact of unfavorable foreign currency exchange rates.
Guinea government: drug lords deposed by ruling junta plotting to topple governmentJuly 12th, 2009 Guinea government warns of coup plotCONAKRY, Guinea — Guinea's military leaders have uncovered a plot to overthrow the government in the poor, unstable West African nation, state radio reported. It said in a report Saturday night that military ruler Capt.
Merck, Portola Pharmaceuticals sign deal worth up to $470 million to develop anticlotting drugJuly 9th, 2009 Merck, Portola in $470M deal for anticlotting drugTRENTON, N.J. — Merck & Co.
Prosecutor: Grenades, ammunition seized from Mexican traffickers belong to Guatemalan armyJune 5th, 2009 Mexico drug cartel's grenades from Guatemalan armyGUATEMALA CITY — Thousands of bullets and grenades that were part of a Mexican drug cartel's weapons cache belong to the Guatemalan army, Guatemala's anti-drug prosecutor said Thursday. Prosecutor Leonel Ruiz said investigators have determined that more than 3,800 bullets and 563 grenades seized outside Guatemala's capital in April following a shootout that left five anti-drug agents dead came from military bases in the Central American nation, which has become a major transshipment point for Colombian cocaine.
European countries using more antivirals against swine flu than US, Mexico, WHO saysMay 12th, 2009 WHO: Europe uses more drugs against swine fluGENEVA — Europe's heavy use of antiviral medication against swine flu does not appear to be creating drug resistance but countries should follow the lead of Mexico and the United States and target the medicine to patients most at risk, the World Health Organization said Tuesday. The swine flu virus has sickened some 5,251 people in 30 countries, with 61 people dead, according to WHO figures.
Swiss drug maker Roche donates over 5M packs of anti-viral Tamiflu to UN health agencyMay 12th, 2009 Roche donates over 5M packs of anti-viral to WHOBASEL, Switzerland — Swiss pharmaceuticals company Roche Holding AG said Tuesday it is donating 5.65 million packets of Tamiflu, one of two anti-viral drugs known to be effective against swine flu, to the World Health Organization. Roche said 5 million packets will be used to replenish stockpiles that were depleted when WHO sent previously donated supplies to poor countries after the appearance of a new type of swine flu, dubbed A(H1N1).
Senate approves nomination of Seattle Police Chief Gil Kerlikowske as drug czarMay 8th, 2009 Senate approves Seattle police chief as drug czarWASHINGTON — The Senate has approved the nomination of Seattle Police Chief Gil Kerlikowske as the national drug czar. Kerlikowske, a 36-year law enforcement veteran, has said he will take a balanced, science-based approach to the job of director of the Office of National Drug Control Policy.
French anti-doping agency says it will not seek sanctions against Lance ArmstrongApril 24th, 2009 France not seeking sanctions against ArmstrongPARIS — France's anti-doping agency says it will not seek sanctions against cyclist Lance Armstrong over a dispute with a drug tester. The AFLD agency said in a statement Friday that it "decided to take into consideration the athlete's written explanations" and will not open disciplinary procedures.
Ranbaxy posts Rs.1,045 crore net loss in 2008March 30th, 2009 MUMBAI - Leading drug maker Ranbaxy Laboratories Monday reported a net loss of Rs.1,044.8 crore ($204 million) for 2008 as against a net profit of Rs.617.7 crore in the previous year. However, the company's total income went up 9.85 percent to Rs.4,681.7 crore in 2008 from Rs.4,261.9 crore in 2007.
Loading ...